Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors

Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty
pharmaceutical company with a lead program in Parkinson's disease, today
announced the appointment of Nan Hutchinson to the Board of Directors. 


"We are extremely pleased that Nan has joined our Board of Directors," said
Rochelle Stenzler, Cynapsus' Chair of the Board. "Nan brings a wealth of
pharmaceutical development and business experience to the Company, including her
vast knowledge of managing the commercialization of early stage pharmaceutical
products. This addition is excellent news for our shareholders and reflects the
Company's commitment to further enhance our Board of Directors with experienced,
independent, pharmaceutical industry veterans." 


Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus added, "We
are very pleased to welcome Nan to the Board. Her experience in strategic
planning, business development and marketing at Bristol-Myers Squibb, Johnson &
Johnson and URL Pharma will be extremely valuable as we begin to plan the
commercialization strategy for APL-130277 for Parkinson's off episodes." 


"Cynapsus has a potentially transformative Parkinson's therapy with important
upcoming milestones and clinical data," said Ms. Hutchinson. "I am delighted to
be joining the Cynapsus Board and look forward to supporting the team as they
deliver on the company's promise."


Ms. Hutchinson has more than twenty-five years of pharmaceutical experience
spanning all aspects of commercialization, including strategic planning,
marketing, business development, sales leadership, talent identification and
development. Over the past decade, Nan was the Senior Vice President of
Marketing and Sales for URL Pharma, a privately held pharmaceutical company,
helping transform the commercial organization and leading to the acquisition by
Takeda Pharmaceutical. Prior to URL, Nan was Senior Vice President of Marketing
at Bristol Myers Squibb where she ran a $2 billion multi-asset portfolio and had
worldwide P&L responsibility in the Global Group. She ran several significant
and profitable business units at Johnson & Johnson, winning several awards. Nan
also founded a successful consulting company focused on helping companies to
accelerate innovation, raise capital and scale commercial operations, and
currently serves as a Life Science Advisor at MaRs Discovery District. Ms.
Hutchinson holds a bachelor's degree of commerce from Mount Allison University
and a Master of Business Administration degree from Boston University.


About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of "OFF" motor
symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an
easy-to-administer, fast-acting reformulation of apomorphine, which is the only
approved drug (in the United States, Europe, Japan and other countries) to
rescue patients from "OFF" episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
("NDA") expected to be submitted in 2016. 


Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on a recent
study and the results of the Company's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients experience "OFF"
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses.


More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.


Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable securities laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements, including
but not limited to those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its Annual Information Form filed
on August 30, 2013 and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although Cynapsus has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements, there may
be other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place undue
reliance on forward-looking statements. Cynapsus does not undertake to update
any forward-looking statements, except in accordance with applicable securities
laws.


Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved
the contents of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
[phone] x225
[e-mail]


Cynapsus Therapeutics
Andrew Williams
COO & CFO
[phone] x253
[e-mail]
www.cynapsus.ca